Västra Hamnen Corp. Finance

• Non-binding term sheet with EQGen Biomedical regarding EQSTEM
• The financial situation is still an issue
• We keep the fair value at SEK 1.30 per share

In connection with the Q1 report, Xintela announced a signed, non-binding term sheet with the US firm EQGen Biomedical regarding EQSTEM, Xintela’s veterinarian joint disease treatment. We expect details to be disclosed once EQGen Biomedical secures funding and the parties announce a license agreement.

We therefore maintain our risk-adjusted motivated value of SEK 1.30 per share. The full report is available here.